Phase 3 Multiple Sclerosis Trial, Recruiting NCT05906992 Sponsor: Celltrion Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Phase 3 Multiple Sclerosis Trial, Recruiting

NCT05906992
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with multiple sclerosis (MS) based on a specific set of recognised diagnostic standards called the revised McDonald criteria.
  • People who have shown signs of recent MS activity, as defined by the trial's guidelines.
  • People whose neurological condition has been stable for at least 30 days before joining.
  • People who score between 0 and 6.0 (inclusive) on a standard MS disability scale called the EDSS, which measures how much MS affects daily functioning.

Who may not be able to join:

  • People who have been diagnosed with primary progressive or secondary progressive MS.
  • People who have had MS for more than 15 years and score 2.0 or below on the EDSS scale at the screening stage.
  • People who are unable to have an MRI scan, or for whom an MRI scan would be medically unsuitable.
  • People who have known serious allergic reactions or medical reasons preventing them from taking corticosteroids (a type of medication), including a drug called methylprednisolone, or any ingredients in the trial medication (confirm with trial site for full details).
  • People who have, or have had in the past, certain medical conditions listed in the trial protocol (confirm with trial site for the full list).
  • People who have recently received, are currently receiving, or are planning to receive certain medications or treatments that are not permitted under the trial protocol (confirm with trial site for the full list).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Minji Ma, Celltrion, Inc.

Phone: +82 32 850 5791

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Celltrion
Registry
ClinicalTrials.gov
Start date
11 January 2024
Est. completion
1 February 2027

Where this trial is recruiting

🇵🇱 Poland

Primary endpoints

Area under the concentration-time curve in PK group; Total number of new GdE lesions on T1-weighted brain MRI in Main study group

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov